摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(4-Cyano-5-methyl-4-phenyl)hexyl]-4-(1-methyl-2-indoloyl)piperazine | 350850-14-5

分子结构分类

中文名称
——
中文别名
——
英文名称
1-[(4-Cyano-5-methyl-4-phenyl)hexyl]-4-(1-methyl-2-indoloyl)piperazine
英文别名
5-[4-(1-Methylindole-2-carbonyl)piperazin-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile
1-[(4-Cyano-5-methyl-4-phenyl)hexyl]-4-(1-methyl-2-indoloyl)piperazine化学式
CAS
350850-14-5
化学式
C28H34N4O
mdl
——
分子量
442.604
InChiKey
HOARPBNQXSNMRP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    33
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    52.3
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound
    申请人:Eisai Co., Ltd.
    公开号:US20040220193A1
    公开(公告)日:2004-11-04
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C 3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R 1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each represents a single bond or an optionally substituted C 1-6 alkylene chain.
    本发明提供了一种具有卓越的拮抗作用,特别是神经元选择性拮抗作用的新化合物。即,提供了下式所示的化合物、其盐或合物。其中,Ar表示可选取的5-至14-成员芳香环等;环A表示选自哌嗪、同哌嗪吡啶等任意一环;环B表示可选取的C3-14碳氢环等;E表示单键、由公式—CO—表示的基团等;X表示单键、氧原子等;R1表示氢原子、卤原子、羟基等;D1、D2、W1和W2相同或不同,每个代表单键或可选取的C1-6烷基链。
  • NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
    申请人:Eisai Co., Ltd.
    公开号:EP1254895A1
    公开(公告)日:2002-11-06
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula -CO-, etc.; X indicates a single bond, an oxygen atom etc.; R1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D1, D2, W1 and W2 are the same as or different from each other and each represents a single bond or an optionally substituted C1-6 alkylene chain.
    本发明提供了一种新型化合物,它具有优异的拮抗作用,特别是神经元选择性拮抗作用。也就是说,本发明提供了由下式表示的化合物、其盐或它们的合物。 式中,Ar 表示任选取代的 5 至 14 元芳香环等;环 A 表示选自哌嗪、均哌嗪哌啶等的任一环;环 B 表示任选取代的 C3-14 碳氢环等。E表示单键、由式-CO-表示的基团等;X表示单键、氧原子等;R1表示氢原子、卤素原子、羟基等;D1、D2、W1 和 W2 彼此相同或不同,各自表示单键或任选取代的 C1-6 亚烷基链。
  • Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1818326A1
    公开(公告)日:2007-08-15
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them: wherein Ar is a thiophene or benzene ring which may be substituted,the ring A is a piperazine ring, homopiperazine ring or piperidine ring which may be substituted, the ring B is a C6-14 aromatic hydrocarbon ring or 5- to 14-membered aromatic heterocyclic ring which may be substituted, the partial structure -D1-E-D2- is a C1-4 alkylene group, W1 and W2 are the same as or different from each other and each represents (1) a single bond or (2) a C1-6 alkylene chain which may be substituted, X is (1) an oxygen atom, a group represented by (2) the formula -NR2- (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted) or (3) -NH-SO2-, R1 is a methyl group, an ethyl group, a n-propyl group or an isopropyl group.
    本发明提供了一种新型化合物,它具有优异的拮抗作用,尤其是神经元选择性拮抗作用。也就是说,本发明提供了由下式(I)代表的化合物、其盐或它们的合物: 其中 Ar 是可被取代的噻吩环或苯环,环 A 是可被取代的哌嗪环、均哌嗪环或哌啶环,环 B 是可被取代的 C6-14 芳烃环或 5-14 元芳香杂环,部分结构 -D1-E-D2- 是 C1-4 烯基、W1和W2彼此相同或不同,各自代表(1)单键或(2)可被取代的C1-6亚烷基链,X是(1)氧原子、由(2)式-NR2-(其中R2表示氢原子)代表的基团或C1-6烷基、或 C1-6 烷基、C3-8 环烷基、低级酰基或可能被取代的 C1-6 烷基磺酰基)或 (3) -NH-SO2- 所代表的基团,R1 是甲基、乙基、正丙基或异丙基。
  • US6906072B1
    申请人:——
    公开号:US6906072B1
    公开(公告)日:2005-06-14
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯